Delcath Systems, HEPZATO KIT
Melphalan is approved by FDA as a liver-directed treatment for uveal melanoma
Nov 2023: The Food and Drug Administration approved HEPZATO KIT (melphalan for Injection/Hepatic Delivery System, Delcath Systems, Inc.) as a liver-directed treatment for adult patients with uveal melanoma who have unresectable h..
China, Clinical trials, hepatocellular carcinoma, JW Therapeutics, Shanghai
JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma
SHANGHAI, CHINA, February 28, 2023 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the init..
durvalumab, hepatocellular carcinoma, tremelimumab
Tremelimumab is approved by FDA in combination with durvalumab for unresectable hepatocellular carcinoma
November 2022: The Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHCC). Efficacy was evaluat..
Atezolizumab, Bevacizumab, nivolumab, Regorafenib, Stivarga, Tecentriq
Drugs approved for treatment of liver cancer
Dec 2021: The following drugs are approved as of date for the treatment of liver cancer:. Please check the prescribing information before taking the drug. Atezolizumab Avastin (Bevacizumab) Bevacizumab Cabometyx (Cabozantinib-S-M..
Liver transplant, Liver transplant in Apollo Chennai
Liver cancer surgery and transplant by Dr. Selvakumar
July 14, 2021: Check out interview of Dr. Selvakumar Naganathan - Clinical Lead - Liver transplantation and HPB surgery, Apollo Hospitals, Chennai. Check out the video and also excerpts of the interview. https://www.youtube.com..
Atezolizumab, Bevacizumab, Latest drugs
Atezolizumab plus Bevacizumab for treatment of liver cancer
July 13th 2021: A novel medication for people with a kind of liver cancer called hepatocellular carcinoma is available that appears to be better than standard therapy (HCC). The Food and Drug Administration (FDA) approved atezoliz..
CABOMETYX, Cabozantinib, Exelixis, FDA, HCC, hepatocellular carcinoma, Sorafenib, USFDA
Cabozantinib is FDA-approved for hepatocellular carcinoma
On January 14, 2019, cabozantinib (CABOMETYX, Exelixis, Inc.) was approved by the Food and Drug Administration for patients with hepatocellular carcinoma (HCC) who have previously been treated with sorafenib. The appr..
Liver cancer treatment in 2023
Burden of liver cancer Liver cancer is a common malignant tumor accounting for more than half of the global liver cancer. The onset of hepatocellular carcinoma (HCC) is hidden, and early symptoms are not obvious. Most people ..
Latest immunotherapy in liver cancer treatment
Liver cancer Liver cancer is currently the fifth most common cause of cancer-related death in the world. The current first-line systemic treatment drug is mainly sorafenib, but usually only prolongs the overall survival of 3 mont..
NK Cell immunotherapy in advanced liver cancer cases
Cases of NK cell immunotherapy for advanced liver cancer 92-year-old advanced cancer patient has complete remission Seven years ago, Ms. M, who was in her 80s, was diagnosed with hepatocellular carcinoma (caused by cancer in the p..